2. confidential2
The issues of cure
▲ Drugs and medical devices become more advanced, but
still pose challenges
▲ Another issue is suboptimal handling of the device
▲ Current issues are:
▲ Complex diseases with a variety of causes and treatments
▲ Overmedication (of antibiotics)
▲ Extensive cure need due to hospitalization
3. confidential3
Mission
▲ Improve the treatment options for patient and surgeon
▲ Improved working
▲ Longer efficacy (degradation)
▲ Target release
▲ Enhanced handling
▲ Better applicators
▲ Extension application areas
▲ Change functional form
4. confidential4
Elements as innovation
▲ New technologies offer new treatment solutions
▲ Biopolymers are used as devices or carriers for drugs or
tissues: viscosupplements and hemostasis products
▲ BioMed Elements has a technology platform to optimize
the behavior of medical devices by tuning the basic
elements of the polymers
6. confidential6
Biomaterials market
Market Size CAGR
Biomaterials 70 B 16%
Plastic surgery 6,5 B 14%
Orthopaedic 22 B 5%
Dental 6,6 B 7%
Hemostasis 1,5 B 4%
Tissue engineering 2,1 B 10%
The key market players are Royal DSM, Wright Medical Technology, Inc., Corbion
N.V., Zimmer Biomet Holdings, Inc., Bayer AG, Carpenter Technology Corporation,
Covalon Technologies Ltd., BASF SE, Invibio Ltd., Berkeley Advanced Biomaterials,
Inc., and Collagen Matrix, Inc. among others.
http://www.biomatin.eu/pdf/Regional_analysis_of_the_biomaterial_market.pdf
http://providencehightech.com/biomaterials-trends-forecasts/
7. confidential7
BioMed Core Technology
Source Material Core Technology Spherical Submicron Particles
▲ Access to well defined spherical submicron particles
▲ Control over parameters (e.g. size, density)
▲ Patented continuous process:
▲ Upscaling is possible
▲ High consistent quality
1µm
8. confidential8
Functional Forms
Suspension Powder GelSponge
Resorbable HemostatResorbable Scaffold Flowable Carrier
Application: Application: Application:Application:
Drug Carrier
Application Areas: orthobiologics, wound management, tissue engineering,
medical aesthetics and cosmetics.
9. confidential9
Business model
▲ Contract research and co-development:
▲ Feasibility study and product optimization
▲ Analytical study
▲ Contract manufacturing:
▲ Medical devices and half fabricates manufacturing
▲ Development own product range:
▲ Developing a range of niche products
10. confidential10
Value proposition
Phase 1:
Feasibility study for
improved or new
product
Phase 2:
Proof of concept;
lock in of IP
Phase 3:
Upscaling of
manufacturing
based on BioMed
expertise and
manufacturing
capabilities
Phase 4:
Manufacturing and
distribution of
device
11. confidential11
Current partners
▲ Netherlands: HCM Medical, Avivia, Fibriant, Leader
Biomedical and Zuyderland hospital.
▲ Europe: Mathys Medical (Switzerland), OST
Developpement (France) and Sirakoss (United Kingdom).
▲ USA: Pro-Tech Design, Alamo Tissue Services, Synergy
BioMedical, Celling Biosciences and Vivex Biomedical.
14. confidential14
Do’s and don’ts
▲ Be stubborn, but also look for people who are even more
stubborn
▲ Be smart on how to persuade investors
▲ Hold perspective on success; by yourself as well as from
others
▲ Use network opportunities
▲ Luck = your effort + what others help you with
15. confidential15
BioMed’s future
▲ Investment need for validation of haemostatic gel
▲ Set up and strengthen partner network
▲ Perform animal study for heavy bleedings product Q2
2018
▲ Market access in ENT surgery products
And what the future brings